Recent News

NeuroInDx is selected for NIH SBIR Commercialization Assistance Program  by the Larta Insitute.

NeuroIndx presents its CTAS prototype at the Society for Neuroscience’s 40th Annual Meeting, San Diego, CA.

Kudo LC, Fields T, Vi N, Bragin A, Karsten SL. CTAS: A novel low-cost capillary-based cell and tissue acquisition system for a wide range of applications. Poster Presentation.

NeuroInDx presents its FAST-MD concept at American Neurological Association’s 135th Annual Meeting in San Francisco, CA.

Morales-Villagrán A, Morales-Rodríguez D, Medina-Ceja L, López-Pérez S, Vi N, Bragin A, Karsten SL and Kudo LC. High-throughput microarray-based microdialysis (FAST-MD) with parallel measurements of brain electrical activity. Poster presentation.

Dr. Karsten along with other panelists discusses the issues related with microdissection and cell specific transcriptome analyses at the Webinar organized by Alzheimer Research Forum.

Alzheimer Research Forum. Live Discussion: Microdissection and Microarrays: Analyzing Selective Cell Vulnerability.

NeuroInDx’s FAST-MD concept is selected for the NIH SBIR Niche Assessment Program (NOT-OD-08-100). Foresight Science and Technology will perform Technology Niche Analyses (TNA™) to assess potential uses of FAST-MD technology and its advantages, competitors, market, price and a commercialization strategy.

NeuroInDx receives NIH/NCRR SBIR Phase II award to further develop and commercialize low cost cell and tissue acquisition system (CTAS).

NeuroInDx presents its CTAS concept and latest results from the epilepsy project at the Experimental Biology meeting, April 24-28. Anaheim, CA.

Karsten SL, Vi N, Bragin A, Mazarati A, Kudo LC. Predicting epilepsy with peripheral blood transcriptome biomarkers during early latent period. Experimental Biology. Annual Meeting of the American Physiological Society. FASEB J. 2010 24:lb28. Poster Presentation.

Kudo LC, Fields T, Vi N, Bragi A, and Karsten SL. CTAS: a novel low-cost capillary-based cell and tissue acquisition system. Experimental Biology 2010. Annual Meeting of the American Physiological Society. FASEB J. 2010 24:lb452. Poster Presentation.

Dr. Karsten presents results of epilepsy project at Epilepsy Pipeline Update Conference in San Francisco organized by Epilepsy Therapy Project.

Karsten SL. Peripheral blood transcriptome biomarkers for the identification of pre-epileptic patients.

NeuroInDx presents results of epilepsy project at AES Annual Meeting. The presentation receives AES Young Investigator Award.

Karsten SL, Vi N, Bragin A, Mazarati A, Kudo LC. Peripheral blood transcriptome biomarkers for the prediction of epilepsy during early latent period. American Epilepsy Society 63d Annual Meeting. Boston, MA. Poster Presentation.

NeuroInDx presents results of epilepsy project at the SFN Annual Meeting.

Vi N, Bragin A, Mazarati A, Karsten SL, Kudo LC. Identification of rat peripheral blood transcriptome biomarkers for the prediction of temporal lobe epilepsy. Society for Neuroscience Annual Meeting. Chicago, IL. Poster Presentation.

NeuroInDx presents results of epilepsy project at the ASHG Annual Meeting.

Vi N, Bragin A, Mazarati A, Kudo LC, Karsten SL. Peripheral blood transcriptome biomarkers to predict epilepsy during early latent period. The American Society of Human Genetics 59th Annual Meeting. Honolulu, HI. Poster Presentation.

The American Epilepsy Society awards NeuroInDx with the Young Investigator Award to present the results of epilepsy project at the AES Annual Meeting in Boston, MA.

NeuroInDx receives NIH/NINDS supplemental support to build a prototype of the prognostic epilepsy microarray.

NeuroInDx receives second NIH/NINDS Phase I SBIR award to identify transcriptome biomarkers for the prediction of temporal lobe epilepsy.

NeuroInDx establishes DNA microarray core facility that will provide gene expression service from tissue/sample acquisition to microarray data analysis and confirmation.

NeuroInDx receives third 2-year NIH/NIMH SBIR Phase I award to develop high-throughput microarray-based microdialysis.

NeuroInDx’s CTAS technology is selected for NIH SBIR Niche Assessment Program (NOT-OD-08-100). Foresight Science and Technology will perform Technology Niche Analyses (TNA™) to assess potential uses of CTAS technology, its advantages, competitors, market, price and a commercialization strategy.

NeuroInDx and The Regents of the University of California executed exclusive license agreement for CTAS technology to NeuroInDx.

NeuroInDx receives supplemental NIH/NINDS Phase I SBIR support for the identification of epilepsy prognostic biomarkers.

NeuroInDx receives first NIH/NCRR Phase I SBIR for the development of low cost capillary based cell and tissue acquisition system (CTAS).

UCLA files international patent application for low cost cell and tissue acquisition system (CTAS).

NeuroInDx, Inc. is founded.